Efficacy of ondanstron in the treatment of schizophrenia

Study of the Effect of ondansetron on Negative Symptoms in Schizophrenia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180505039530N1

Enrollment

Registered

2018-05-29

Start date

2018-02-18

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: 8 mg/day of Tablets ondansetron as intervention group for 12 months. Intervention 2: Control group: The control group will receive placebo for 12 months.

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Ages of subjects were between 25 to 65 years Is based on DSM-IV diagnosis of schizophrenia The patient or patient's guardian consent to participate. PANSS score at the beginning of the project is more than 55.

Exclusion criteria

Exclusion criteria: Patients treated with clozapine Pregnancy and breast feeding Any serious medical or neurological problem Hypersensitivity to ondansetron Substance abuse and alcohol Patients who choose to be excluded.

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: The beginning of the study and 4, 8, 12 months after beginning of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Moteshakerarani

Kashan University of Medical Sciences

moteshakerarani-a@kaums.ac.ir+98 31 5554 2999

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026